Mobile

A PHASE 2, OPEN-LABEL STUDY TO ASSESS THE EFFICACY AND SAFETY OF LENALIDOMIDE IN COMBINATION WITH CETUXIMAB IN PRETREATED SUBJECTS WITH KRAS MUTANT METASTATIC COLORECTAL CANCER

Update Il y a 4 ans
Reference: EUCTR2009-012665-61

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

•Phase 2a To determine the Maximal Tolerated Dose (MTD) of lenalidomide in combination with cetuximab in subjects with KRAS mutant metastatic CRC. •Phase 2b To determine the response rate in subjects with KRAS mutant metastatic CRC.

Inclusion criteria

  • Colorectal Cancer

Links